Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350654 | 0.83 | KDM4E (0.30) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL20929171 | 0.83 | KDM4E (0.30) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL31736077 | 0.81 | KDM4E (0.37) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL3150946 | 0.80 | CYP3A4 (0.52) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL1507410 | 0.79 | CYP3A4 (0.48) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL15689490 | 0.75 | CREBBP (0.36) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL28815369 | 0.74 | ALDH1A1 (0.48) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL28422107 | 0.74 | ERN1 (0.37) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL14992925 | 0.74 | PTGDR2 (0.42) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 | |
| SCHEMBL21132629 | 0.73 | KMT2A (0.35) | CYP3A4KDM4EMEN1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282752-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-12371415-B2 | Quinazoline derivative salt crystal form, preparation method and application | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2022266458-A1 | 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| WO-2019196619-A1 | QUINAZOLINE DERIVATIVE SALT-FORM CRYSTAL FORM, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | CYP3A4 4156/4885KDM4E 4285/4885MEN1 415/4885 |
| US-12371415-B2 | Quinazoline derivative salt crystal form, preparation method and application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | CYP3A4 826/4885KDM4E 1478/4885MEN1 114/4885 |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | CYP3A4 826/4885KDM4E 1478/4885MEN1 114/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | CYP3A4 4156/4885KDM4E 4285/4885MEN1 415/4885 |
| US-20250282752-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | CYP3A4 826/4885KDM4E 1478/4885MEN1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.